Literature DB >> 20592711

Screening: HPV testing for cervical cancer: the good, the bad, and the ugly.

Philip E Castle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20592711     DOI： 10.1038/nrclinonc.2010.96

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.

Authors:  M H Stoler; M Schiffman
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

2.  Too much of a good thing? Physician practices and patient willingness for less frequent pap test screening intervals.

Authors:  Helen I Meissner; Jasmin A Tiro; K Robin Yabroff; David A Haggstrom; Steven S Coughlin
Journal:  Med Care       Date:  2010-03       Impact factor: 2.983

3.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Authors:  Guglielmo Ronco; Paolo Giorgi-Rossi; Francesca Carozzi; Massimo Confortini; Paolo Dalla Palma; Annarosa Del Mistro; Bruno Ghiringhello; Salvatore Girlando; Anna Gillio-Tos; Laura De Marco; Carlo Naldoni; Paola Pierotti; Raffaella Rizzolo; Patrizia Schincaglia; Manuel Zorzi; Marco Zappa; Nereo Segnan; Jack Cuzick
Journal:  Lancet Oncol       Date:  2010-01-18       Impact factor: 41.316

4.  Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007.

Authors:  K Robin Yabroff; Mona Saraiya; Helen I Meissner; David A Haggstrom; Louise Wideroff; Gigi Yuan; Zahava Berkowitz; William W Davis; Vicki B Benard; Steven S Coughlin
Journal:  Ann Intern Med       Date:  2009-11-03       Impact factor: 25.391

5.  Pap testing and sexual activity among young women in the United States.

Authors:  Mona Saraiya; Gladys Martinez; Katherine Glaser; Shalini Kulasingam
Journal:  Obstet Gynecol       Date:  2009-12       Impact factor: 7.661

6.  Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial.

Authors:  Albertus G Siebers; Paul J J M Klinkhamer; Johanna M M Grefte; Leon F A G Massuger; Judith E M Vedder; Angelique Beijers-Broos; Johan Bulten; Marc Arbyn
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

7.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.

Authors:  N W J Bulkmans; J Berkhof; L Rozendaal; F J van Kemenade; A J P Boeke; S Bulk; F J Voorhorst; R H M Verheijen; K van Groningen; M E Boon; W Ruitinga; M van Ballegooijen; P J F Snijders; C J L M Meijer
Journal:  Lancet       Date:  2007-10-04       Impact factor: 79.321

8.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

Authors:  Henry C Kitchener; Maribel Almonte; Claire Thomson; Paula Wheeler; Alexandra Sargent; Boyka Stoykova; Clare Gilham; Helene Baysson; Christopher Roberts; Robin Dowie; Mina Desai; Jean Mather; Andrew Bailey; Andrew Turner; Sue Moss; Julian Peto
Journal:  Lancet Oncol       Date:  2009-06-17       Impact factor: 41.316

9.  HPV screening for cervical cancer in rural India.

Authors:  Rengaswamy Sankaranarayanan; Bhagwan M Nene; Surendra S Shastri; Kasturi Jayant; Richard Muwonge; Atul M Budukh; Sanjay Hingmire; Sylla G Malvi; Ranjit Thorat; Ashok Kothari; Roshan Chinoy; Rohini Kelkar; Shubhada Kane; Sangeetha Desai; Vijay R Keskar; Raghevendra Rajeshwarkar; Nandkumar Panse; Ketayun A Dinshaw
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

10.  Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.

Authors:  Joakim Dillner; Matejka Rebolj; Philippe Birembaut; Karl-Ulrich Petry; Anne Szarewski; Christian Munk; Silvia de Sanjose; Pontus Naucler; Belen Lloveras; Susanne Kjaer; Jack Cuzick; Marjolein van Ballegooijen; Christine Clavel; Thomas Iftner
Journal:  BMJ       Date:  2008-10-13
  10 in total
  4 in total

1.  Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples.

Authors:  Yi-Shan Yang; Karen Smith-McCune; Teresa M Darragh; Yvonne Lai; Ju-Hwa Lin; Ting-Chang Chang; Hsiao-Yun Guo; Tiea Kesler; Alicia Carter; Philip E Castle; Shuling Cheng
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

2.  Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.

Authors:  G S Ogilvie; M Krajden; D J van Niekerk; R E Martin; T G Ehlen; K Ceballos; L W Smith; L Kan; D A Cook; S Peacock; G C E Stuart; E L Franco; A J Coldman
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

3.  Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.

Authors:  Sarah Preisler; Matejka Rebolj; Ditte Møller Ejegod; Elsebeth Lynge; Carsten Rygaard; Jesper Bonde
Journal:  BMC Cancer       Date:  2016-07-20       Impact factor: 4.430

4.  Does the primary screening test influence women's anxiety and intention to screen for cervical cancer? A randomized survey of Norwegian women.

Authors:  Emily A Burger; Mari Nygård; Dorte Gyrd-Hansen; Tron Anders Moger; Ivar Sonbo Kristiansen
Journal:  BMC Public Health       Date:  2014-04-15       Impact factor: 3.295
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.